News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Provectus Biopharmaceuticals Inc. To Discuss Outline Of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma On Conference Call


6/12/2014 9:38:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT), (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time. Management will discuss the outline of the Company’s proposed Phase 3 study of PV-10 in the treatment of melanoma, developments in the use of PV-10 in other cancer indications, as well as PH-10 and news regarding its use. Management will also discuss its potential plans to monetize its PV-10 and PH-10 assets with various contemplated license and co-development transactions.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES